Septerna

Novo inks $2.2B deal for Septerna's preclinical obesity programs

Novo offered more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1.

Nick Paul Taylor May 14, 2025 7:00am

A young researcher with wavy black hair and wearing a white coat looks into a microscope

Septerna drops lead asset over side effects 4 months after IPO

Feb 18, 2025 9:43am

Why biotechs can benefit from the 'rational' IPO environment

Jan 24, 2025 10:30am

What can we learn from 2024’s biotech IPOs?

Dec 6, 2024 8:44am

Septerna goes public with upsized offering of $288M

Oct 25, 2024 10:29am

Septerna plans $158M IPO to fund readouts for GPCR pipeline

Oct 21, 2024 8:30am